Abstract:Background: Viral resistance to existing inhibitors and the time-dependent effectiveness of neuraminidase inhibitors have limited the number of antivirals that can be used for prophylaxis and therapeutic treatment of severe influenza infection. Thus, there is an urgent need to develop new drugs to prevent and treat influenza infection. Objective: The aim of this study was to design and synthesize a novel series of 2-ureidonicotinamide derivatives, and evaluate their anti-IAV activities. Furthermore, we predicted the abilities of these compounds inhibiting PA-PB1 subunit and forecasted the docking poses of these compounds with RNA polymerase protein (PDB ID 3CM8). Method: The novel designed compounds were synthesized using classical methods of organic chemistry and tested in vitro for their abilities inhibiting RNP and against influenza A virus. In addition, the 23 synthesized molecules were subjected to the generated pharmacophore Hypo1 to forecast the activity target PA-PB1 subunit of RNA polymerase. The ADMET pharmacokinetic parameters were calculated by the ADMET modules in Discovery Studio 2016. The docking results helped us to demonstrate the possible interactions between these compounds with 3CM8. Results: The synthesized 2-ureidonicotinamide derivatives were characterized as potent anti-influenza inhibitors. The target compounds 7b and 7c demonstrated significant antiviral activities, and could be considered as novel lead compounds of antiviral inhibitors. In addition, compound 7b revealed suitable ADME properties expressed, and might be a significant RNA polymerase inhibitor targeting PA-PB1 subunit based on the predictable results and the docking results. Conclusion: This study revealed a novel series of compounds that might be useful in the search for an effective drug against influenza virus.

Discovery of the first series of small molecule H5N1 entry inhibitors.

Structure-activity relationships of saponin derivatives: a series of entry inhibitors for highly pathogenic H5N1 influenza virus.

Synthesis and Biological Evaluation of Analogs of Methyl Ursolate 3-O-β-chacotrioside As H5N1 Viral Entry Inhibitors

Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.

Synthesis and In Vitro Anti-Influenza Virus Evaluation of Novel Sialic Acid (C-5 and C-9)-Pentacyclic Triterpene Derivatives

Discovery of Pentacyclic Triterpenoids As Potential Entry Inhibitors of Influenza Viruses.

Design, Synthesis And Biological Activity Evaluation Of Novel Conjugated Sialic Acid And Pentacyclic Triterpene Derivatives As Anti-Influenza Entry Inhibitors

CL-385319 Inhibits H5N1 Avian Influenza A Virus Infection by Blocking Viral Entry

Potent Inhibitor Design Against H1N1 Swine Influenza: Structure-Based and Molecular Dynamics Analysis for M2 Inhibitors from Traditional Chinese Medicine Database.

Discovery and structural optimization of 3-O-β-chacotriosyl oleanane-type triterpenoids as potent entry inhibitors of SARS-CoV-2 virus infections

Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity

Discovery of Peptidomimetic Spiropyrrolidine Derivatives As Novel 3clpro Inhibitors Against SARS-CoV-2

Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus

Screening from the World'S Largest Tcm Database Against H1n1 Virus

Discovery and SAR Study of Piperidine-Based Derivatives As Novel Influenza Virus Inhibitors.

Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus

Discovery of new quinoline derivatives bearing 1-aryl-1,2,3-triazole motif as influenza H1N1 virus neuraminidase inhibitors

Design, Synthesis and Biological Evaluation of Amino Acids-Oleanolic Acid Conjugates As Influenza Virus Inhibitors.

Synthesis of C-4-modified Zanamivir Analogs As Neuraminidase Inhibitors and Their Anti-Aiv Activities

Design, synthesis, and biological activity of a novel series of 2-ureidonicotinamide derivatives against influenza A virus

Potent sialic acid inhibitors that target influenza A virus hemagglutinin